Patients with Thyroid Eye Disease Initiating Teprotumumab: A Real-World Cohort Study Using the Linked IRIS-Komodo Database.

At baseline, 79% had ≥1 eye sign or symptom (proptosis: 45%; diplopia: 29%).

Among 356 patients with CAS recorded, 91% had active disease (CAS ≥3/7 or 4/10).

Teprotumumab was initiated within 12 months of thyroid eye disease diagnosis in 70% of patients.

Retreatment with teprotumumab occurred in 10% of patients completing the first course, 26% of whom completed the second course.